nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—Protein Kinase Inhibitors—Vandetanib—thyroid cancer	0.475	1	CiPCiCtD
Ruxolitinib—RET—thyroid cancer	0.174	1	CbGaD
Ruxolitinib—LTK—Vandetanib—thyroid cancer	0.0424	0.169	CbGbCtD
Ruxolitinib—PLK4—Vandetanib—thyroid cancer	0.0355	0.141	CbGbCtD
Ruxolitinib—MKNK2—Sorafenib—thyroid cancer	0.0322	0.128	CbGbCtD
Ruxolitinib—TAOK2—Sorafenib—thyroid cancer	0.0322	0.128	CbGbCtD
Ruxolitinib—RET—Vandetanib—thyroid cancer	0.0306	0.122	CbGbCtD
Ruxolitinib—MAP3K7—Sorafenib—thyroid cancer	0.0255	0.102	CbGbCtD
Ruxolitinib—MAP3K19—Vandetanib—thyroid cancer	0.0204	0.0811	CbGbCtD
Ruxolitinib—RET—Sorafenib—thyroid cancer	0.0185	0.0735	CbGbCtD
Ruxolitinib—MAP3K19—Sorafenib—thyroid cancer	0.0123	0.0489	CbGbCtD
Ruxolitinib—Blood pressure systolic increased—Sorafenib—thyroid cancer	0.00257	0.154	CcSEcCtD
Ruxolitinib—RET—parathyroid gland—thyroid cancer	0.00117	0.0379	CbGeAlD
Ruxolitinib—CYP3A4—Vandetanib—thyroid cancer	0.000868	0.00346	CbGbCtD
Ruxolitinib—JAK1—neck—thyroid cancer	0.000558	0.0181	CbGeAlD
Ruxolitinib—GRK7—head—thyroid cancer	0.000541	0.0175	CbGeAlD
Ruxolitinib—CYP3A4—Sorafenib—thyroid cancer	0.000523	0.00208	CbGbCtD
Ruxolitinib—ANKK1—head—thyroid cancer	0.000495	0.016	CbGeAlD
Ruxolitinib—PLK3—trachea—thyroid cancer	0.000437	0.0142	CbGeAlD
Ruxolitinib—JAK1—saliva-secreting gland—thyroid cancer	0.000435	0.0141	CbGeAlD
Ruxolitinib—PRKCE—thyroid gland—thyroid cancer	0.000431	0.014	CbGeAlD
Ruxolitinib—BMP2K—neck—thyroid cancer	0.000417	0.0135	CbGeAlD
Ruxolitinib—DAPK2—saliva-secreting gland—thyroid cancer	0.000415	0.0134	CbGeAlD
Ruxolitinib—RPS6KA6—thyroid gland—thyroid cancer	0.000415	0.0134	CbGeAlD
Ruxolitinib—PRKG2—head—thyroid cancer	0.00041	0.0133	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Vandetanib—thyroid cancer	0.000402	0.024	CcSEcCtD
Ruxolitinib—GRK1—head—thyroid cancer	0.000391	0.0127	CbGeAlD
Ruxolitinib—CLK2—saliva-secreting gland—thyroid cancer	0.000386	0.0125	CbGeAlD
Ruxolitinib—PRKCE—head—thyroid cancer	0.000383	0.0124	CbGeAlD
Ruxolitinib—RPS6KA6—head—thyroid cancer	0.000368	0.0119	CbGeAlD
Ruxolitinib—PLK1—head—thyroid cancer	0.000368	0.0119	CbGeAlD
Ruxolitinib—MAST1—head—thyroid cancer	0.000368	0.0119	CbGeAlD
Ruxolitinib—RET—neck—thyroid cancer	0.000355	0.0115	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Vandetanib—thyroid cancer	0.000354	0.0212	CcSEcCtD
Ruxolitinib—DCLK3—head—thyroid cancer	0.000349	0.0113	CbGeAlD
Ruxolitinib—NUAK2—saliva-secreting gland—thyroid cancer	0.000348	0.0113	CbGeAlD
Ruxolitinib—PLK3—thyroid gland—thyroid cancer	0.000346	0.0112	CbGeAlD
Ruxolitinib—DCLK1—trachea—thyroid cancer	0.000336	0.0109	CbGeAlD
Ruxolitinib—JAK1—trachea—thyroid cancer	0.000336	0.0109	CbGeAlD
Ruxolitinib—CAMK1D—trachea—thyroid cancer	0.000328	0.0106	CbGeAlD
Ruxolitinib—Neutropenia—Vandetanib—thyroid cancer	0.000325	0.0194	CcSEcCtD
Ruxolitinib—CAMK1—thyroid gland—thyroid cancer	0.000324	0.0105	CbGeAlD
Ruxolitinib—DAPK2—trachea—thyroid cancer	0.00032	0.0104	CbGeAlD
Ruxolitinib—CYP3A4—Doxorubicin—thyroid cancer	0.000318	0.00126	CbGbCtD
Ruxolitinib—PLK1—Erlotinib—Vandetanib—thyroid cancer	0.000317	0.246	CbGdCrCtD
Ruxolitinib—MARK2—thyroid gland—thyroid cancer	0.000314	0.0102	CbGeAlD
Ruxolitinib—Weight decreased—Vandetanib—thyroid cancer	0.000314	0.0188	CcSEcCtD
Ruxolitinib—Infestation NOS—Vandetanib—thyroid cancer	0.00031	0.0185	CcSEcCtD
Ruxolitinib—Infestation—Vandetanib—thyroid cancer	0.00031	0.0185	CcSEcCtD
Ruxolitinib—PLK3—head—thyroid cancer	0.000307	0.00994	CbGeAlD
Ruxolitinib—Urinary tract infection—Vandetanib—thyroid cancer	0.000301	0.018	CcSEcCtD
Ruxolitinib—CLK2—trachea—thyroid cancer	0.000298	0.00966	CbGeAlD
Ruxolitinib—LTK—head—thyroid cancer	0.000296	0.0096	CbGeAlD
Ruxolitinib—Haematuria—Vandetanib—thyroid cancer	0.000295	0.0177	CcSEcCtD
Ruxolitinib—Myelosuppression—Epirubicin—thyroid cancer	0.000294	0.0176	CcSEcCtD
Ruxolitinib—MAP3K7—saliva-secreting gland—thyroid cancer	0.000293	0.00949	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Vandetanib—thyroid cancer	0.000293	0.0175	CcSEcCtD
Ruxolitinib—Epistaxis—Vandetanib—thyroid cancer	0.000292	0.0175	CcSEcCtD
Ruxolitinib—TAOK2—thyroid gland—thyroid cancer	0.000291	0.00941	CbGeAlD
Ruxolitinib—TYK2—saliva-secreting gland—thyroid cancer	0.000288	0.00932	CbGeAlD
Ruxolitinib—CAMK1—head—thyroid cancer	0.000287	0.0093	CbGeAlD
Ruxolitinib—MKNK2—saliva-secreting gland—thyroid cancer	0.000284	0.00919	CbGeAlD
Ruxolitinib—Haemoglobin—Vandetanib—thyroid cancer	0.000279	0.0167	CcSEcCtD
Ruxolitinib—MARK2—head—thyroid cancer	0.000279	0.00903	CbGeAlD
Ruxolitinib—Haemorrhage—Vandetanib—thyroid cancer	0.000278	0.0166	CcSEcCtD
Ruxolitinib—Myelosuppression—Doxorubicin—thyroid cancer	0.000272	0.0163	CcSEcCtD
Ruxolitinib—NUAK2—trachea—thyroid cancer	0.000268	0.00869	CbGeAlD
Ruxolitinib—PRKCE—lymph node—thyroid cancer	0.000268	0.00868	CbGeAlD
Ruxolitinib—JAK3—thyroid gland—thyroid cancer	0.000267	0.00865	CbGeAlD
Ruxolitinib—DCLK1—thyroid gland—thyroid cancer	0.000265	0.0086	CbGeAlD
Ruxolitinib—JAK1—thyroid gland—thyroid cancer	0.000265	0.0086	CbGeAlD
Ruxolitinib—CAMK1D—thyroid gland—thyroid cancer	0.000259	0.00839	CbGeAlD
Ruxolitinib—PHKG2—thyroid gland—thyroid cancer	0.000258	0.00834	CbGeAlD
Ruxolitinib—RPS6KA6—lymph node—thyroid cancer	0.000258	0.00834	CbGeAlD
Ruxolitinib—PLK1—lymph node—thyroid cancer	0.000258	0.00834	CbGeAlD
Ruxolitinib—DAPK2—thyroid gland—thyroid cancer	0.000253	0.0082	CbGeAlD
Ruxolitinib—MAP3K3—saliva-secreting gland—thyroid cancer	0.000252	0.00817	CbGeAlD
Ruxolitinib—STK16—thyroid gland—thyroid cancer	0.000249	0.00807	CbGeAlD
Ruxolitinib—HIPK2—thyroid gland—thyroid cancer	0.000248	0.00803	CbGeAlD
Ruxolitinib—Malnutrition—Vandetanib—thyroid cancer	0.000242	0.0145	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Sorafenib—thyroid cancer	0.000239	0.0143	CcSEcCtD
Ruxolitinib—DAPK3—thyroid gland—thyroid cancer	0.000238	0.00771	CbGeAlD
Ruxolitinib—JAK3—head—thyroid cancer	0.000237	0.00767	CbGeAlD
Ruxolitinib—CLK2—thyroid gland—thyroid cancer	0.000236	0.00764	CbGeAlD
Ruxolitinib—DCLK1—head—thyroid cancer	0.000235	0.00763	CbGeAlD
Ruxolitinib—JAK1—head—thyroid cancer	0.000235	0.00763	CbGeAlD
Ruxolitinib—TAOK3—saliva-secreting gland—thyroid cancer	0.00023	0.00745	CbGeAlD
Ruxolitinib—CAMK1D—head—thyroid cancer	0.00023	0.00744	CbGeAlD
Ruxolitinib—PHKG2—head—thyroid cancer	0.000229	0.0074	CbGeAlD
Ruxolitinib—MAP3K7—trachea—thyroid cancer	0.000226	0.00732	CbGeAlD
Ruxolitinib—DYRK1A—thyroid gland—thyroid cancer	0.000223	0.00722	CbGeAlD
Ruxolitinib—BMPR2—thyroid gland—thyroid cancer	0.000222	0.00719	CbGeAlD
Ruxolitinib—TYK2—trachea—thyroid cancer	0.000222	0.00719	CbGeAlD
Ruxolitinib—STK16—head—thyroid cancer	0.000221	0.00716	CbGeAlD
Ruxolitinib—HIPK2—head—thyroid cancer	0.00022	0.00712	CbGeAlD
Ruxolitinib—Neutropenia—Sorafenib—thyroid cancer	0.000219	0.0131	CcSEcCtD
Ruxolitinib—MKNK2—trachea—thyroid cancer	0.000219	0.00709	CbGeAlD
Ruxolitinib—MAP3K19—head—thyroid cancer	0.000215	0.00698	CbGeAlD
Ruxolitinib—PLK3—lymph node—thyroid cancer	0.000215	0.00696	CbGeAlD
Ruxolitinib—NUAK2—thyroid gland—thyroid cancer	0.000212	0.00687	CbGeAlD
Ruxolitinib—Weight decreased—Sorafenib—thyroid cancer	0.000212	0.0127	CcSEcCtD
Ruxolitinib—DAPK3—head—thyroid cancer	0.000211	0.00684	CbGeAlD
Ruxolitinib—CLK2—head—thyroid cancer	0.000209	0.00678	CbGeAlD
Ruxolitinib—Infestation NOS—Sorafenib—thyroid cancer	0.000209	0.0125	CcSEcCtD
Ruxolitinib—Infestation—Sorafenib—thyroid cancer	0.000209	0.0125	CcSEcCtD
Ruxolitinib—LTK—lymph node—thyroid cancer	0.000208	0.00672	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.000205	0.0122	CcSEcCtD
Ruxolitinib—ROCK1—head—thyroid cancer	0.000203	0.00657	CbGeAlD
Ruxolitinib—JAK2—trachea—thyroid cancer	0.000202	0.00654	CbGeAlD
Ruxolitinib—CAMK1—lymph node—thyroid cancer	0.000201	0.00651	CbGeAlD
Ruxolitinib—CAMK2G—thyroid gland—thyroid cancer	0.000199	0.00644	CbGeAlD
Ruxolitinib—BMP2K—thyroid gland—thyroid cancer	0.000199	0.00644	CbGeAlD
Ruxolitinib—DYRK1A—head—thyroid cancer	0.000198	0.00641	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Sorafenib—thyroid cancer	0.000198	0.0118	CcSEcCtD
Ruxolitinib—BMPR2—head—thyroid cancer	0.000197	0.00638	CbGeAlD
Ruxolitinib—Epistaxis—Sorafenib—thyroid cancer	0.000197	0.0118	CcSEcCtD
Ruxolitinib—LRRK2—thyroid gland—thyroid cancer	0.000197	0.00638	CbGeAlD
Ruxolitinib—Infection—Vandetanib—thyroid cancer	0.000196	0.0117	CcSEcCtD
Ruxolitinib—MARK2—lymph node—thyroid cancer	0.000195	0.00632	CbGeAlD
Ruxolitinib—MAP3K3—trachea—thyroid cancer	0.000195	0.0063	CbGeAlD
Ruxolitinib—Nervous system disorder—Vandetanib—thyroid cancer	0.000194	0.0116	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Vandetanib—thyroid cancer	0.000193	0.0116	CcSEcCtD
Ruxolitinib—Skin disorder—Vandetanib—thyroid cancer	0.000192	0.0115	CcSEcCtD
Ruxolitinib—Haemoglobin—Sorafenib—thyroid cancer	0.000188	0.0113	CcSEcCtD
Ruxolitinib—Haemorrhage—Sorafenib—thyroid cancer	0.000187	0.0112	CcSEcCtD
Ruxolitinib—Herpes zoster—Epirubicin—thyroid cancer	0.000183	0.011	CcSEcCtD
Ruxolitinib—TAOK2—lymph node—thyroid cancer	0.000181	0.00585	CbGeAlD
Ruxolitinib—MAP3K2—thyroid gland—thyroid cancer	0.00018	0.00584	CbGeAlD
Ruxolitinib—MAP3K7—thyroid gland—thyroid cancer	0.000179	0.00579	CbGeAlD
Ruxolitinib—TAOK3—trachea—thyroid cancer	0.000177	0.00574	CbGeAlD
Ruxolitinib—BMP2K—head—thyroid cancer	0.000176	0.00571	CbGeAlD
Ruxolitinib—CAMK2G—head—thyroid cancer	0.000176	0.00571	CbGeAlD
Ruxolitinib—TYK2—thyroid gland—thyroid cancer	0.000176	0.00568	CbGeAlD
Ruxolitinib—LRRK2—head—thyroid cancer	0.000175	0.00566	CbGeAlD
Ruxolitinib—MKNK2—thyroid gland—thyroid cancer	0.000173	0.00561	CbGeAlD
Ruxolitinib—IRAK1—thyroid gland—thyroid cancer	0.000173	0.00561	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00017	0.0102	CcSEcCtD
Ruxolitinib—Fatigue—Vandetanib—thyroid cancer	0.00017	0.0102	CcSEcCtD
Ruxolitinib—Herpes zoster—Doxorubicin—thyroid cancer	0.00017	0.0101	CcSEcCtD
Ruxolitinib—RET—thyroid gland—thyroid cancer	0.000169	0.00547	CbGeAlD
Ruxolitinib—JAK3—lymph node—thyroid cancer	0.000166	0.00537	CbGeAlD
Ruxolitinib—JAK1—lymph node—thyroid cancer	0.000165	0.00534	CbGeAlD
Ruxolitinib—DCLK1—lymph node—thyroid cancer	0.000165	0.00534	CbGeAlD
Ruxolitinib—PLK4—lymph node—thyroid cancer	0.000164	0.00531	CbGeAlD
Ruxolitinib—Malnutrition—Sorafenib—thyroid cancer	0.000163	0.00976	CcSEcCtD
Ruxolitinib—CAMK1D—lymph node—thyroid cancer	0.000161	0.00521	CbGeAlD
Ruxolitinib—MAP3K2—head—thyroid cancer	0.00016	0.00518	CbGeAlD
Ruxolitinib—PHKG2—lymph node—thyroid cancer	0.00016	0.00518	CbGeAlD
Ruxolitinib—JAK2—thyroid gland—thyroid cancer	0.00016	0.00517	CbGeAlD
Ruxolitinib—DAPK2—lymph node—thyroid cancer	0.000157	0.00509	CbGeAlD
Ruxolitinib—Body temperature increased—Vandetanib—thyroid cancer	0.000156	0.00934	CcSEcCtD
Ruxolitinib—TYK2—head—thyroid cancer	0.000156	0.00504	CbGeAlD
Ruxolitinib—STK16—lymph node—thyroid cancer	0.000155	0.00501	CbGeAlD
Ruxolitinib—HIPK2—lymph node—thyroid cancer	0.000154	0.00499	CbGeAlD
Ruxolitinib—MAP3K3—thyroid gland—thyroid cancer	0.000154	0.00498	CbGeAlD
Ruxolitinib—MKNK2—head—thyroid cancer	0.000154	0.00498	CbGeAlD
Ruxolitinib—Anaemia—Sorafenib—thyroid cancer	0.000151	0.00902	CcSEcCtD
Ruxolitinib—RET—head—thyroid cancer	0.00015	0.00485	CbGeAlD
Ruxolitinib—DAPK3—lymph node—thyroid cancer	0.000148	0.00479	CbGeAlD
Ruxolitinib—CLK2—lymph node—thyroid cancer	0.000147	0.00474	CbGeAlD
Ruxolitinib—Bone pain—Epirubicin—thyroid cancer	0.000144	0.00861	CcSEcCtD
Ruxolitinib—JAK2—head—thyroid cancer	0.000142	0.00459	CbGeAlD
Ruxolitinib—Asthenia—Vandetanib—thyroid cancer	0.000142	0.00847	CcSEcCtD
Ruxolitinib—TAOK3—thyroid gland—thyroid cancer	0.00014	0.00454	CbGeAlD
Ruxolitinib—Pruritus—Vandetanib—thyroid cancer	0.00014	0.00836	CcSEcCtD
Ruxolitinib—DYRK1A—lymph node—thyroid cancer	0.000138	0.00449	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.000138	0.00825	CcSEcCtD
Ruxolitinib—BMPR2—lymph node—thyroid cancer	0.000138	0.00447	CbGeAlD
Ruxolitinib—MAP3K3—head—thyroid cancer	0.000137	0.00442	CbGeAlD
Ruxolitinib—Bone pain—Doxorubicin—thyroid cancer	0.000133	0.00797	CcSEcCtD
Ruxolitinib—Infection—Sorafenib—thyroid cancer	0.000132	0.00791	CcSEcCtD
Ruxolitinib—NUAK2—lymph node—thyroid cancer	0.000132	0.00427	CbGeAlD
Ruxolitinib—Nervous system disorder—Sorafenib—thyroid cancer	0.000131	0.00781	CcSEcCtD
Ruxolitinib—Dizziness—Vandetanib—thyroid cancer	0.000131	0.00781	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Sorafenib—thyroid cancer	0.00013	0.0078	CcSEcCtD
Ruxolitinib—Skin disorder—Sorafenib—thyroid cancer	0.000129	0.00774	CcSEcCtD
Ruxolitinib—TAOK3—head—thyroid cancer	0.000124	0.00403	CbGeAlD
Ruxolitinib—Headache—Vandetanib—thyroid cancer	0.000124	0.0074	CcSEcCtD
Ruxolitinib—BMP2K—lymph node—thyroid cancer	0.000123	0.004	CbGeAlD
Ruxolitinib—CAMK2G—lymph node—thyroid cancer	0.000123	0.004	CbGeAlD
Ruxolitinib—LRRK2—lymph node—thyroid cancer	0.000122	0.00396	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000115	0.00688	CcSEcCtD
Ruxolitinib—Fatigue—Sorafenib—thyroid cancer	0.000115	0.00687	CcSEcCtD
Ruxolitinib—MAP3K2—lymph node—thyroid cancer	0.000112	0.00363	CbGeAlD
Ruxolitinib—MAP3K7—lymph node—thyroid cancer	0.000111	0.0036	CbGeAlD
Ruxolitinib—TYK2—lymph node—thyroid cancer	0.000109	0.00353	CbGeAlD
Ruxolitinib—MKNK2—lymph node—thyroid cancer	0.000108	0.00349	CbGeAlD
Ruxolitinib—IRAK1—lymph node—thyroid cancer	0.000108	0.00349	CbGeAlD
Ruxolitinib—Body temperature increased—Sorafenib—thyroid cancer	0.000105	0.0063	CcSEcCtD
Ruxolitinib—RET—lymph node—thyroid cancer	0.000105	0.0034	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.0001	0.00599	CcSEcCtD
Ruxolitinib—JAK2—lymph node—thyroid cancer	9.92e-05	0.00321	CbGeAlD
Ruxolitinib—MAP3K3—lymph node—thyroid cancer	9.56e-05	0.0031	CbGeAlD
Ruxolitinib—Asthenia—Sorafenib—thyroid cancer	9.56e-05	0.00572	CcSEcCtD
Ruxolitinib—Pruritus—Sorafenib—thyroid cancer	9.42e-05	0.00564	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	9.27e-05	0.00554	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Epirubicin—thyroid cancer	8.83e-05	0.00528	CcSEcCtD
Ruxolitinib—Dizziness—Sorafenib—thyroid cancer	8.81e-05	0.00527	CcSEcCtD
Ruxolitinib—TAOK3—lymph node—thyroid cancer	8.72e-05	0.00282	CbGeAlD
Ruxolitinib—Headache—Sorafenib—thyroid cancer	8.34e-05	0.00499	CcSEcCtD
Ruxolitinib—Pancytopenia—Epirubicin—thyroid cancer	8.22e-05	0.00492	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	8.17e-05	0.00489	CcSEcCtD
Ruxolitinib—Neutropenia—Epirubicin—thyroid cancer	8.09e-05	0.00484	CcSEcCtD
Ruxolitinib—DYRK1A—Doxorubicin—Epirubicin—thyroid cancer	7.88e-05	0.0611	CbGdCrCtD
Ruxolitinib—DYRK1A—Daunorubicin—Epirubicin—thyroid cancer	7.88e-05	0.0611	CbGdCrCtD
Ruxolitinib—DYRK1A—Idarubicin—Epirubicin—thyroid cancer	7.88e-05	0.0611	CbGdCrCtD
Ruxolitinib—Weight increased—Epirubicin—thyroid cancer	7.88e-05	0.00471	CcSEcCtD
Ruxolitinib—Weight decreased—Epirubicin—thyroid cancer	7.83e-05	0.00468	CcSEcCtD
Ruxolitinib—Infestation NOS—Epirubicin—thyroid cancer	7.72e-05	0.00462	CcSEcCtD
Ruxolitinib—Infestation—Epirubicin—thyroid cancer	7.72e-05	0.00462	CcSEcCtD
Ruxolitinib—Pancytopenia—Doxorubicin—thyroid cancer	7.61e-05	0.00455	CcSEcCtD
Ruxolitinib—Urinary tract infection—Epirubicin—thyroid cancer	7.5e-05	0.00449	CcSEcCtD
Ruxolitinib—Neutropenia—Doxorubicin—thyroid cancer	7.49e-05	0.00448	CcSEcCtD
Ruxolitinib—Haematuria—Epirubicin—thyroid cancer	7.36e-05	0.0044	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Epirubicin—thyroid cancer	7.3e-05	0.00437	CcSEcCtD
Ruxolitinib—DYRK1A—Epirubicin—Doxorubicin—thyroid cancer	7.29e-05	0.0565	CbGdCrCtD
Ruxolitinib—DYRK1A—Daunorubicin—Doxorubicin—thyroid cancer	7.29e-05	0.0565	CbGdCrCtD
Ruxolitinib—DYRK1A—Idarubicin—Doxorubicin—thyroid cancer	7.29e-05	0.0565	CbGdCrCtD
Ruxolitinib—Weight increased—Doxorubicin—thyroid cancer	7.29e-05	0.00436	CcSEcCtD
Ruxolitinib—Epistaxis—Epirubicin—thyroid cancer	7.28e-05	0.00435	CcSEcCtD
Ruxolitinib—Weight decreased—Doxorubicin—thyroid cancer	7.25e-05	0.00433	CcSEcCtD
Ruxolitinib—Infestation NOS—Doxorubicin—thyroid cancer	7.14e-05	0.00427	CcSEcCtD
Ruxolitinib—Infestation—Doxorubicin—thyroid cancer	7.14e-05	0.00427	CcSEcCtD
Ruxolitinib—Haemoglobin—Epirubicin—thyroid cancer	6.96e-05	0.00417	CcSEcCtD
Ruxolitinib—Urinary tract infection—Doxorubicin—thyroid cancer	6.94e-05	0.00415	CcSEcCtD
Ruxolitinib—Haemorrhage—Epirubicin—thyroid cancer	6.93e-05	0.00414	CcSEcCtD
Ruxolitinib—Haematuria—Doxorubicin—thyroid cancer	6.81e-05	0.00407	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Doxorubicin—thyroid cancer	6.75e-05	0.00404	CcSEcCtD
Ruxolitinib—Epistaxis—Doxorubicin—thyroid cancer	6.74e-05	0.00403	CcSEcCtD
Ruxolitinib—Haemoglobin—Doxorubicin—thyroid cancer	6.44e-05	0.00385	CcSEcCtD
Ruxolitinib—Haemorrhage—Doxorubicin—thyroid cancer	6.41e-05	0.00383	CcSEcCtD
Ruxolitinib—Malnutrition—Epirubicin—thyroid cancer	6.03e-05	0.00361	CcSEcCtD
Ruxolitinib—Flatulence—Epirubicin—thyroid cancer	5.94e-05	0.00355	CcSEcCtD
Ruxolitinib—Malnutrition—Doxorubicin—thyroid cancer	5.58e-05	0.00334	CcSEcCtD
Ruxolitinib—Anaemia—Epirubicin—thyroid cancer	5.57e-05	0.00333	CcSEcCtD
Ruxolitinib—Flatulence—Doxorubicin—thyroid cancer	5.5e-05	0.00329	CcSEcCtD
Ruxolitinib—PLK4—Doxorubicin—Epirubicin—thyroid cancer	5.38e-05	0.0417	CbGdCrCtD
Ruxolitinib—PLK1—Daunorubicin—Epirubicin—thyroid cancer	5.38e-05	0.0417	CbGdCrCtD
Ruxolitinib—PLK1—Idarubicin—Epirubicin—thyroid cancer	5.38e-05	0.0417	CbGdCrCtD
Ruxolitinib—PLK4—Idarubicin—Epirubicin—thyroid cancer	5.38e-05	0.0417	CbGdCrCtD
Ruxolitinib—PLK1—Doxorubicin—Epirubicin—thyroid cancer	5.38e-05	0.0417	CbGdCrCtD
Ruxolitinib—Anaemia—Doxorubicin—thyroid cancer	5.16e-05	0.00309	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	5.1e-05	0.00305	CcSEcCtD
Ruxolitinib—PLK4—Idarubicin—Doxorubicin—thyroid cancer	4.98e-05	0.0386	CbGdCrCtD
Ruxolitinib—PLK1—Daunorubicin—Doxorubicin—thyroid cancer	4.98e-05	0.0386	CbGdCrCtD
Ruxolitinib—PLK4—Epirubicin—Doxorubicin—thyroid cancer	4.98e-05	0.0386	CbGdCrCtD
Ruxolitinib—PLK1—Idarubicin—Doxorubicin—thyroid cancer	4.98e-05	0.0386	CbGdCrCtD
Ruxolitinib—PLK1—Epirubicin—Doxorubicin—thyroid cancer	4.98e-05	0.0386	CbGdCrCtD
Ruxolitinib—Infection—Epirubicin—thyroid cancer	4.89e-05	0.00292	CcSEcCtD
Ruxolitinib—Nervous system disorder—Epirubicin—thyroid cancer	4.83e-05	0.00289	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Epirubicin—thyroid cancer	4.82e-05	0.00288	CcSEcCtD
Ruxolitinib—Skin disorder—Epirubicin—thyroid cancer	4.78e-05	0.00286	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	4.72e-05	0.00282	CcSEcCtD
Ruxolitinib—Infection—Doxorubicin—thyroid cancer	4.52e-05	0.00271	CcSEcCtD
Ruxolitinib—Nervous system disorder—Doxorubicin—thyroid cancer	4.47e-05	0.00267	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Doxorubicin—thyroid cancer	4.46e-05	0.00267	CcSEcCtD
Ruxolitinib—Skin disorder—Doxorubicin—thyroid cancer	4.42e-05	0.00265	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Epirubicin—thyroid cancer	4.25e-05	0.00254	CcSEcCtD
Ruxolitinib—Fatigue—Epirubicin—thyroid cancer	4.24e-05	0.00254	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Doxorubicin—thyroid cancer	3.93e-05	0.00235	CcSEcCtD
Ruxolitinib—Fatigue—Doxorubicin—thyroid cancer	3.93e-05	0.00235	CcSEcCtD
Ruxolitinib—Body temperature increased—Epirubicin—thyroid cancer	3.89e-05	0.00233	CcSEcCtD
Ruxolitinib—Body temperature increased—Doxorubicin—thyroid cancer	3.6e-05	0.00215	CcSEcCtD
Ruxolitinib—Asthenia—Epirubicin—thyroid cancer	3.53e-05	0.00211	CcSEcCtD
Ruxolitinib—Pruritus—Epirubicin—thyroid cancer	3.48e-05	0.00208	CcSEcCtD
Ruxolitinib—Asthenia—Doxorubicin—thyroid cancer	3.27e-05	0.00195	CcSEcCtD
Ruxolitinib—Dizziness—Epirubicin—thyroid cancer	3.26e-05	0.00195	CcSEcCtD
Ruxolitinib—Pruritus—Doxorubicin—thyroid cancer	3.22e-05	0.00193	CcSEcCtD
Ruxolitinib—Headache—Epirubicin—thyroid cancer	3.08e-05	0.00184	CcSEcCtD
Ruxolitinib—Dizziness—Doxorubicin—thyroid cancer	3.01e-05	0.0018	CcSEcCtD
Ruxolitinib—Headache—Doxorubicin—thyroid cancer	2.85e-05	0.00171	CcSEcCtD
Ruxolitinib—TYK2—Disease—HIF1A—thyroid cancer	2.29e-06	4.47e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—NRAS—thyroid cancer	2.29e-06	4.46e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—KRAS—thyroid cancer	2.29e-06	4.46e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—PTEN—thyroid cancer	2.28e-06	4.45e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TERT—thyroid cancer	2.27e-06	4.44e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—KRAS—thyroid cancer	2.27e-06	4.43e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CDK1—thyroid cancer	2.26e-06	4.41e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling by Wnt—AKT1—thyroid cancer	2.24e-06	4.38e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TERT—thyroid cancer	2.24e-06	4.36e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—NRAS—thyroid cancer	2.23e-06	4.34e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—NRAS—thyroid cancer	2.23e-06	4.34e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—NRAS—thyroid cancer	2.22e-06	4.33e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PTCH1—thyroid cancer	2.22e-06	4.32e-05	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—AKT1—thyroid cancer	2.21e-06	4.32e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—NRAS—thyroid cancer	2.21e-06	4.31e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—HRAS—thyroid cancer	2.2e-06	4.29e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—AKT1—thyroid cancer	2.2e-06	4.29e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—HRAS—thyroid cancer	2.19e-06	4.28e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—NRG1—thyroid cancer	2.19e-06	4.28e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Metabolism—AKT1—thyroid cancer	2.18e-06	4.26e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HIF1A—thyroid cancer	2.17e-06	4.24e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—KRAS—thyroid cancer	2.16e-06	4.22e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—AKT1—thyroid cancer	2.16e-06	4.22e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—TP53—thyroid cancer	2.16e-06	4.21e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—NRAS—thyroid cancer	2.16e-06	4.21e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—HRAS—thyroid cancer	2.16e-06	4.21e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—AKT1—thyroid cancer	2.16e-06	4.21e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—NRAS—thyroid cancer	2.15e-06	4.2e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HIF1A—thyroid cancer	2.14e-06	4.17e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—BRAF—thyroid cancer	2.09e-06	4.08e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—PTGS2—thyroid cancer	2.08e-06	4.05e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—KRAS—thyroid cancer	2.08e-06	4.05e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—KRAS—thyroid cancer	2.07e-06	4.03e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—NRAS—thyroid cancer	2.07e-06	4.03e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—HRAS—thyroid cancer	2.07e-06	4.03e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—NRAS—thyroid cancer	2.03e-06	3.97e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—TP53—thyroid cancer	2.03e-06	3.96e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SST—thyroid cancer	2.03e-06	3.95e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NRG1—thyroid cancer	2.02e-06	3.95e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NDUFA13—thyroid cancer	2.02e-06	3.95e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—KRAS—thyroid cancer	1.97e-06	3.84e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—PTEN—thyroid cancer	1.96e-06	3.83e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—HRAS—thyroid cancer	1.95e-06	3.81e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CALCA—thyroid cancer	1.95e-06	3.8e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—HRAS—thyroid cancer	1.94e-06	3.79e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—AKT1—thyroid cancer	1.94e-06	3.79e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—HRAS—thyroid cancer	1.93e-06	3.77e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NRG1—thyroid cancer	1.93e-06	3.76e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—KRAS—thyroid cancer	1.92e-06	3.74e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—KRAS—thyroid cancer	1.92e-06	3.74e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—NRAS—thyroid cancer	1.92e-06	3.74e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—KRAS—thyroid cancer	1.91e-06	3.73e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—AKT1—thyroid cancer	1.9e-06	3.72e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—NRAS—thyroid cancer	1.9e-06	3.71e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CHST14—thyroid cancer	1.9e-06	3.71e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—KRAS—thyroid cancer	1.9e-06	3.71e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—BRAF—thyroid cancer	1.9e-06	3.7e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—PTEN—thyroid cancer	1.88e-06	3.68e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—NRAS—thyroid cancer	1.88e-06	3.68e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—GPCR downstream signaling—AKT1—thyroid cancer	1.88e-06	3.66e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NRG1—thyroid cancer	1.87e-06	3.65e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—NRAS—thyroid cancer	1.87e-06	3.64e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—KRAS—thyroid cancer	1.86e-06	3.62e-05	CbGpPWpGaD
Ruxolitinib—PHKG2—Metabolism—AKT1—thyroid cancer	1.85e-06	3.62e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—KRAS—thyroid cancer	1.85e-06	3.61e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—HRAS—thyroid cancer	1.84e-06	3.59e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—TP53—thyroid cancer	1.84e-06	3.58e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—AKT1—thyroid cancer	1.82e-06	3.56e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—TERT—thyroid cancer	1.82e-06	3.54e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NRG1—thyroid cancer	1.81e-06	3.54e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—PTEN—thyroid cancer	1.81e-06	3.53e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CCND1—thyroid cancer	1.81e-06	3.53e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—BRAF—thyroid cancer	1.8e-06	3.51e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—KRAS—thyroid cancer	1.78e-06	3.47e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—BRAF—thyroid cancer	1.77e-06	3.46e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CDK1—thyroid cancer	1.77e-06	3.44e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—HRAS—thyroid cancer	1.76e-06	3.44e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—HRAS—thyroid cancer	1.76e-06	3.43e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—KRAS—thyroid cancer	1.75e-06	3.42e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—NRAS—thyroid cancer	1.75e-06	3.41e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—PTEN—thyroid cancer	1.75e-06	3.41e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HIF1A—thyroid cancer	1.74e-06	3.39e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TERT—thyroid cancer	1.73e-06	3.37e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—AKT1—thyroid cancer	1.72e-06	3.35e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—AKT1—thyroid cancer	1.7e-06	3.33e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—NRAS—thyroid cancer	1.68e-06	3.28e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TERT—thyroid cancer	1.68e-06	3.27e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—HRAS—thyroid cancer	1.67e-06	3.26e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HIF1A—thyroid cancer	1.65e-06	3.23e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—KRAS—thyroid cancer	1.65e-06	3.22e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—KRAS—thyroid cancer	1.64e-06	3.2e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—HRAS—thyroid cancer	1.63e-06	3.18e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—HRAS—thyroid cancer	1.63e-06	3.18e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TERT—thyroid cancer	1.63e-06	3.18e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—HRAS—thyroid cancer	1.62e-06	3.17e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—AKT1—thyroid cancer	1.62e-06	3.17e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—KRAS—thyroid cancer	1.62e-06	3.16e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—NRAS—thyroid cancer	1.62e-06	3.15e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—HRAS—thyroid cancer	1.62e-06	3.15e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—KRAS—thyroid cancer	1.61e-06	3.14e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HIF1A—thyroid cancer	1.61e-06	3.13e-05	CbGpPWpGaD
Ruxolitinib—JAK3—GPCR downstream signaling—AKT1—thyroid cancer	1.58e-06	3.09e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—HRAS—thyroid cancer	1.58e-06	3.08e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—HRAS—thyroid cancer	1.57e-06	3.07e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—NRAS—thyroid cancer	1.56e-06	3.04e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—AKT1—thyroid cancer	1.56e-06	3.04e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HIF1A—thyroid cancer	1.56e-06	3.04e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—AKT1—thyroid cancer	1.55e-06	3.03e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PTGS2—thyroid cancer	1.53e-06	2.99e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HPGD—thyroid cancer	1.53e-06	2.99e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CCND1—thyroid cancer	1.53e-06	2.98e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—HRAS—thyroid cancer	1.51e-06	2.95e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—KRAS—thyroid cancer	1.51e-06	2.94e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—PTEN—thyroid cancer	1.49e-06	2.91e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—HRAS—thyroid cancer	1.49e-06	2.9e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—AKT1—thyroid cancer	1.48e-06	2.88e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PTEN—thyroid cancer	1.47e-06	2.88e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—PTEN—thyroid cancer	1.45e-06	2.83e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—KRAS—thyroid cancer	1.45e-06	2.82e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—BRAF—thyroid cancer	1.44e-06	2.81e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—AKT1—thyroid cancer	1.44e-06	2.81e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—AKT1—thyroid cancer	1.44e-06	2.81e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—AKT1—thyroid cancer	1.43e-06	2.8e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TP53—thyroid cancer	1.43e-06	2.79e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—AKT1—thyroid cancer	1.43e-06	2.78e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NRG1—thyroid cancer	1.42e-06	2.76e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—NRAS—thyroid cancer	1.41e-06	2.76e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—PTEN—thyroid cancer	1.4e-06	2.74e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—HRAS—thyroid cancer	1.4e-06	2.73e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—AKT1—thyroid cancer	1.39e-06	2.72e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—HRAS—thyroid cancer	1.39e-06	2.72e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—KRAS—thyroid cancer	1.39e-06	2.71e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—AKT1—thyroid cancer	1.39e-06	2.71e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—HRAS—thyroid cancer	1.38e-06	2.69e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—BRAF—thyroid cancer	1.37e-06	2.67e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—HRAS—thyroid cancer	1.37e-06	2.67e-05	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—AKT1—thyroid cancer	1.36e-06	2.66e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—KRAS—thyroid cancer	1.34e-06	2.62e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—AKT1—thyroid cancer	1.34e-06	2.61e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PTEN—thyroid cancer	1.34e-06	2.61e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—AKT1—thyroid cancer	1.33e-06	2.6e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—NRAS—thyroid cancer	1.33e-06	2.6e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—BRAF—thyroid cancer	1.33e-06	2.59e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—NRAS—thyroid cancer	1.32e-06	2.57e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—AKT1—thyroid cancer	1.31e-06	2.56e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CCND1—thyroid cancer	1.31e-06	2.56e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CCND1—thyroid cancer	1.29e-06	2.52e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—NRAS—thyroid cancer	1.29e-06	2.52e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—BRAF—thyroid cancer	1.29e-06	2.52e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HRAS—thyroid cancer	1.28e-06	2.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TERT—thyroid cancer	1.27e-06	2.48e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PTEN—thyroid cancer	1.27e-06	2.47e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—NRAS—thyroid cancer	1.25e-06	2.45e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PTEN—thyroid cancer	1.25e-06	2.43e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—AKT1—thyroid cancer	1.24e-06	2.41e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—HRAS—thyroid cancer	1.23e-06	2.4e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—AKT1—thyroid cancer	1.23e-06	2.4e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—KRAS—thyroid cancer	1.22e-06	2.37e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—AKT1—thyroid cancer	1.22e-06	2.37e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HIF1A—thyroid cancer	1.22e-06	2.37e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—AKT1—thyroid cancer	1.21e-06	2.35e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—NRAS—thyroid cancer	1.19e-06	2.33e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—thyroid cancer	1.19e-06	2.33e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—HRAS—thyroid cancer	1.18e-06	2.31e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTGS2—thyroid cancer	1.16e-06	2.27e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—KRAS—thyroid cancer	1.15e-06	2.24e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—HRAS—thyroid cancer	1.14e-06	2.22e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—KRAS—thyroid cancer	1.13e-06	2.21e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NRAS—thyroid cancer	1.13e-06	2.21e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—AKT1—thyroid cancer	1.13e-06	2.21e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NRAS—thyroid cancer	1.11e-06	2.17e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—KRAS—thyroid cancer	1.11e-06	2.17e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PTEN—thyroid cancer	1.1e-06	2.14e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—AKT1—thyroid cancer	1.09e-06	2.12e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—KRAS—thyroid cancer	1.08e-06	2.1e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—NRAS—thyroid cancer	1.07e-06	2.09e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—AKT1—thyroid cancer	1.04e-06	2.04e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—HRAS—thyroid cancer	1.03e-06	2.02e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—KRAS—thyroid cancer	1.03e-06	2e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTEN—thyroid cancer	1.01e-06	1.98e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—BRAF—thyroid cancer	1.01e-06	1.97e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—AKT1—thyroid cancer	1.01e-06	1.96e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—thyroid cancer	1.01e-06	1.96e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCND1—thyroid cancer	9.99e-07	1.95e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—NRAS—thyroid cancer	9.79e-07	1.91e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—KRAS—thyroid cancer	9.74e-07	1.9e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HRAS—thyroid cancer	9.74e-07	1.9e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCND1—thyroid cancer	9.7e-07	1.89e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PTEN—thyroid cancer	9.65e-07	1.88e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HRAS—thyroid cancer	9.62e-07	1.88e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—KRAS—thyroid cancer	9.58e-07	1.87e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HRAS—thyroid cancer	9.45e-07	1.84e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCND1—thyroid cancer	9.41e-07	1.84e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PTEN—thyroid cancer	9.37e-07	1.83e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—KRAS—thyroid cancer	9.23e-07	1.8e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HRAS—thyroid cancer	9.17e-07	1.79e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—AKT1—thyroid cancer	9.14e-07	1.78e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PTEN—thyroid cancer	9.08e-07	1.77e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NRAS—thyroid cancer	9.04e-07	1.76e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TPR—thyroid cancer	8.81e-07	1.72e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—HRAS—thyroid cancer	8.73e-07	1.7e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	8.66e-07	1.69e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—thyroid cancer	8.66e-07	1.69e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NRAS—thyroid cancer	8.61e-07	1.68e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—AKT1—thyroid cancer	8.6e-07	1.68e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—thyroid cancer	8.52e-07	1.66e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—AKT1—thyroid cancer	8.5e-07	1.66e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—KRAS—thyroid cancer	8.43e-07	1.64e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NRAS—thyroid cancer	8.36e-07	1.63e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—AKT1—thyroid cancer	8.35e-07	1.63e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HRAS—thyroid cancer	8.28e-07	1.62e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HRAS—thyroid cancer	8.14e-07	1.59e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NRAS—thyroid cancer	8.1e-07	1.58e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—AKT1—thyroid cancer	8.1e-07	1.58e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—HRAS—thyroid cancer	7.84e-07	1.53e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—KRAS—thyroid cancer	7.78e-07	1.52e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—AKT1—thyroid cancer	7.71e-07	1.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—AKT1—thyroid cancer	7.62e-07	1.49e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KRAS—thyroid cancer	7.41e-07	1.45e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCND1—thyroid cancer	7.35e-07	1.43e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—AKT1—thyroid cancer	7.31e-07	1.43e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KRAS—thyroid cancer	7.19e-07	1.4e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—AKT1—thyroid cancer	7.19e-07	1.4e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HRAS—thyroid cancer	7.16e-07	1.4e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PTEN—thyroid cancer	7.1e-07	1.38e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KRAS—thyroid cancer	6.97e-07	1.36e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—AKT1—thyroid cancer	6.92e-07	1.35e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HRAS—thyroid cancer	6.62e-07	1.29e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC5A5—thyroid cancer	6.59e-07	1.29e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—thyroid cancer	6.58e-07	1.28e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—thyroid cancer	6.39e-07	1.25e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NRAS—thyroid cancer	6.33e-07	1.24e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—AKT1—thyroid cancer	6.33e-07	1.23e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HRAS—thyroid cancer	6.3e-07	1.23e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—thyroid cancer	6.2e-07	1.21e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HRAS—thyroid cancer	6.11e-07	1.19e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HRAS—thyroid cancer	5.93e-07	1.16e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—AKT1—thyroid cancer	5.84e-07	1.14e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—AKT1—thyroid cancer	5.56e-07	1.08e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—RXRA—thyroid cancer	5.54e-07	1.08e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KRAS—thyroid cancer	5.45e-07	1.06e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—AKT1—thyroid cancer	5.4e-07	1.05e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—AKT1—thyroid cancer	5.23e-07	1.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—thyroid cancer	4.84e-07	9.45e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HRAS—thyroid cancer	4.63e-07	9.04e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKT1—thyroid cancer	4.09e-07	7.98e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPARG—thyroid cancer	3.5e-07	6.82e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS2—thyroid cancer	2.75e-07	5.37e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTEN—thyroid cancer	2.4e-07	4.68e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKT1—thyroid cancer	1.38e-07	2.7e-06	CbGpPWpGaD
